Introduction
RELAPSING MULTIPLE SCLEROSIS
Ofatumumab is a fully human, anti-CD20 monoclonal antibody (mAb) approved for relapsing multiple sclerosis (RMS) in many countries.Ofatumumab approval was based on the ASCLEPIOS I (NCT02792218) and ASCLEPIOS II (NCT02792231) Phase 3 studies, which demonstrated superior efficacy versus teriflunomide and a favorable benefit–risk profile up to 2.5 years.To further assess the benefit–risk profile of ofatumumab in RMS and its longer-term tolerability, patients from ofatumumab studies (ASCLEPIOS I/II,Emerging data indicate that early initiation of high-efficacy therapies for RMS improves longer-term outcomes compared with delayed initiation of, or escalation from lower efficacy therapies.We report the efficacy and safety of ofatumumab in patients with RMS, for up to 4 years.